AcelRx Pharmaceuticals

Talphera's scientific research addresses DSUVIA, a sufentanil sublingual tablet intended to treat acute pain in medically supervised settings.

Mr. Adams has chaired the Talphera Board since February 2013 and Impel NeuroPharma's board since January 2020; he became Impel NeuroPharma's CEO in May 2020. He has chaired Akebia Therapeutics' board since December 2018.

Prior to joining Talphera, Mr. Dasu served as Vice President of Medical Device Engineering at Anesiva, Inc., and as Vice President of Manufacturing and Device Development at AlgoRx Pharmaceuticals, Inc., a pain management company that merged with Corgentech, Inc., in December 2005.

Ms. Broadfoot has been CFO of aTyr Pharma since July 2018. From January 2017 to July 2018, she was CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals.

Marina Bozilenko has been a director since March 2021 and has more than 30 years of investment banking and healthcare experience. Bozilenko has been President, CEO, and a board member at Biothea Pharma, Inc. since June 2021, and a strategic advisor to William Blair & Company since February 2021.

Talphera is developing Niyad, nafamostat, for renal replacement therapy in dialysis patients who cannot tolerate heparin or have an increased risk of bleeding

Talphera is developing Niyad, nafamostat, for renal replacement therapy in dialysis patients who cannot tolerate heparin or have an increased risk of bleeding

The company explains what cookies are and how it uses them in its Cookie Policy.

Talphera's Privacy Policy describes information that may be collected from Site users.

Talphera's Privacy Policy describes personal information that may be collected from Site users.

The Site provides information for general informational and educational purposes.

The site provides information for general informational and educational purposes.